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Hypersensitivity pneumonitis recognised in a single pulmonary 
unit, between 2005 and 2015: comparison with recently proposed 
diagnostic criteria
Abstract
Introduction:	Hypersensitivity	pneumonitis	(HP)	is	the	third	most	common	interstitial	lung	disease	after	idiopathic	pulmonary	
fibrosis	and	nonspecific	 interstitial	 pneumonia.	Pathogenesis	of	HP	 is	 related	 to	 repeated	exposure	 to	 inhaled	environmental	
antigens	that	sensitise	the	susceptible,	genetically	predisposed	persons.	
The	aim	of	the	present	retrospective	study	was	to	summarise	the	diagnostic	methods	used	in	consecutive	patients	with	HP,	
recognised	in	a single	pulmonary	unit,	between	2005	and	2015,	and	to	compare	them	with	current	diagnostic	criteria.
Material and methods:	135	patients,	68	males,	67	females,	median	age	53	years	(18–75	years),	entered	the	study.	Chest	CT	
features	characteristic	of	HP	were	defined	as:	mosaic	attenuation	of	lung	parenchyma,	air	trapping	and/or	ill-defined	centrilobular	
nodules.	Lymphocytosis	in	BAL	was	defined	as	≥	30%.
Results:	Median	time	from	first	symptoms	to	diagnosis	was	12	months.	The	exposure	to	one	or	more	allergens	was	found	in	94%	of	
patients,	chest	CT	features	characteristic	of	HP	have	been	reported	in	87%,	BAL	lymphocytosis	—	in	86%.	
According	to	recent	diagnostic	criteria	—	in	54%	of	patients,	clinical	diagnosis	of	HP	was	confident,	in	16%	—	probable,	in	26%	—	possible	
and	in	4%	—	unlikely.	The	confirmation	of	HP	with	lung	biopsy	has	been	obtained	in	36%	of	non-confident	cases	(16%	of	the	study	group).
Conclusion:	HP	diagnosis	was	confirmed	according	to	current	diagnostic	criteria	in	70%	of	patients	diagnosed	between	2005	and	
2015.	Contradictions	to	lung	biopsy	have	been	the	main	reason	for	inability	to	confirm	HP	in	non-confident	cases.	
Key words: hypersensitivity	pneumonitis,	diagnostic	criteria,	high	resolution	chest	computed	tomography,	bronchoalveolar	lavage
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Introduction
Hypersensitivity pneumonitis (HP) is the third 
most common interstitial lung disease after idio-
pathic pulmonary fibrosis (IPF) and nonspecific 
interstitial pneumonitis (NSIP) [1, 2]. The inciden-
ce rate of HP has been calculated as 0.9/100 000/
year in the United Kingdom [3], 1/100000/year in 
Denmark [1], and 1.28–1.94/100000/year in the US 
[4]. The data concerning HP epidemiology in Po-
land confirmed the incidence rate of 1.26/100 000 
in 1990–1994 [5] and 1.7/100 000 in 2000–2009 [6].
Pathogenesis of HP is related to repeated expo-
sure to inhaled environmental antigens that sensitise 
the susceptible, genetically predisposed persons. The 
causative agents are divided into 6 groups: bacteria, 
fungi, mycobacteria, animal and plant proteins, che-
micals and metals [7, 8]. Most of inducing antigens 
are avian proteins (bird keepers’ lung, feather duvet 
lung), nevertheless, the exposure to microorganisms/
mould containing aerosols (humidifier lung, air 
conditioner lung, hot tub lung, summer-type HP ) or 
to microorganisms/mould colonising hay and straw 
(farmer’s lung) are also frequently described [9–12]. 
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Two clinical phases of HP are distinguished 
presently: acute phase (< 6 months, with pul-
monary pathology fully reversible) and chronic 
phase (≥ 6 months, with irreversible lung chan-
ges) [13]. The prolonged exposure to the antigens 
may result in chronic inflammatory lung disease 
with pro-fibrotic phenotype [14]. 
Systemic manifestations of HP consist of 
general malaise, increased body temperature, 
arthralgia or muscle pain, which develop usu-
ally few hours after the antigen exposure [15]. 
Pulmonary symptoms, such as productive or 
non-productive cough, chest tightness, decrease 
of exercise tolerance and/or exertional dyspnoea 
are most frequent manifestations of chronic HP. 
On auscultation, transient bibasilar crackles are 
noted in the acute phase of disease, whereas in-
spiratory rales, wheezing, or inspiratory squeaks 
are described in chronic phase [13, 16]. 
Most characteristic radiological features of HP 
described in chest computed tomography (chest 
CT) in the acute phase are the following: mosaic 
lung attenuation, with the areas of ground glass 
opacities and air trapping (so called “head che-
ese” appearance), and/or ill-defined centrilobular 
nodules [10, 16]. Upper and middle parts of the 
lungs are mostly affected [16]. Chest CT changes 
described in chronic phase of HP consist mostly 
of foci of peribronchovascular fibrosis and honey-
combing, which may occur in any zonal distri-
bution, with relative sparing of the lung bases. 
Nevertheless, mosaic attenuation, air trapping and 
areas of ground glass attenuation often persist [17]. 
Many algorithms of HP recognition have been 
proposed recently, but none of them is recom-
mended as the universal mode of HP diagnosing.
The general agreement is that the diagnostic 
path of HP has to be composed of several steps: 
1. Identification of agent possibly responsible 
for the symptoms of the disease (via detailed 
anamnesis). Demonstration of specific IgG 
antibodies against various antigens in serum 
of exposed persons, which is helpful only in 
patients with symptomatic disease. 
2. Identification of characteristic radiological 
pattern of changes on chest CT.
3. Increased cellularity and lymphocytosis in 
bronchoalveolar lavage (BAL).
4. Characteristic pattern of lung pathology in 
the specimen obtained on transbronchial 
lung biopsy (TBLB) or transbronchial cryobi-
opsy (TBCB): the presence of poorly formed 
granulomas and/or inflammatory infiltration 
composed of lymphocytes and plasmocytes, 
with bronchocentric distribution [13, 18]. 
5. Surgical lung biopsy (SLB) should be con-
sidered if the diagnosis of HP is uncertain, 
despite the implementation of the above 
mentioned procedures.
The aim of the present retrospective study 
was to summarise the diagnostic methods used 
in the patients with HP recognised in a single 
pulmonary unit between 2005 and 2015 and to 
compare them with current diagnostic criteria 
proposed recently [13].
Material and methods
All the consecutive patients discharged 
between 2005 and 2015 with the diagnosis 
of HP entered the study. The data concerning 
exposure to antigens as well as signs and symp-
toms of the disease have been obtained from 
medical records. Time from the first symptoms 
appearance to diagnosis has been calculated. 
The data concerning radiological pattern of 
chest CT changes as well as BAL results have 
been elicited from the hospital database. The 
description of pathological changes in the lung 
biopsy specimens have been obtained from the 
Department of Pathology. 
The criteria of chest CT features characteri-
stic of HP have been described as: mosaic atte-
nuation of lung parenchyma with the presence 
of air trapping and/or ill-defined centrilobular 
nodules (Fig. 1A, B). In case of lung fibrosis, 
signs of air trapping and persisting features of 
mosaic attenuation have been regarded charac-
teristic (Fig. 2A, B). 
Lymphocytosis in BAL was defined as equal 
or higher than 30%. This arbitrary cut-off has 
been chosen, as it exceeds twice the upper li-
mit of reference value in our laboratory. It also 
corresponds to suggestions of other authors 
[15, 19, 20].
The pathological reports have been conside-
red characteristic of HP in case of chronic bron-
chiolitis with lymphoplasmacytic infiltrations 
and/or poorly formed non-necrotising granulomas 
or at least — with solitary giant cells (Fig. 3). The 
bronchiolocentric distribution of inflammatory or 
fibrotic lesions have been also classified as the 
pathological feature of HP. The infective cause of 
granulomas have been excluded by specific tissue 
staining for acid fast bacilli (Ziehl-Neelsen) or 
fungi (Grocott). 
For analysis of HP probability, according 
to recently proposed algorithm, the authors ap-
plied diagnostic categories defined by Vasakova 
et al. [13] (Fig. 4).
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Figure 1. Acute	HP,	HRCT	on	inspiration,	axial	view;	A	—	case	1.	Poor-
ly	defined	centrilobular	nodules,	some	of	them	confluent;	B	—	case	2.	
Areas	of	ground	glass	opacities	and	of	air	 trapping	causing	mosaic	
lung	attenuation	pattern
Figure 2. Case	3	—	chronic	HP,	chest	CT	on	inspiration;	A	—	frontal	
view,	B	—	coronal	view.	Patchy	fibrosis	with	traction	bronchiectasis	
and	 honeycombing	 with	 superimposed	 ground	 glass	 opacities	 and	
some	centrilobular	nodules,	upper	lung	predominance
A
B
A
B
A B
Figure 3. Hypersensitivity	pneumonitis,	microscopic	image;	A	—	lung	parenchyma	section	with	diffuse,	uniform	inflammatory	infiltration	of	lym-
phocytes	and	plasmocytes,	without	destruction	of	parenchyma.	Among	the	inflammatory	infiltration	there	are	poorly	formed	granulomas	(arrows).	
Low	magnification;	B	—	lung	parenchyma	with	two	weakly	formed	granulomas	composed	mainly	of	giant	cells	(arrows).	High	magnification
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The study has been approved by the Bioethi-
cal Committee of National Tuberculosis and Lung 
Diseases Research Institute No 14/2019
Results
Medical database contained 135 records of pa-
tients discharged with the diagnosis of HP ( ICD 10: 
J67.0-9) in between 2005 and 2015. There were 68 
males, 67 females, median age 53 years (18–75 years).
The median time from first symptoms to 
diagnosis of HP was 12 months (range — 2 mon-
ths to 30 years). In 15 patients the disease has 
been symptomatic for the period shorter than 6 
months, in 56 — between 6 and 12 months, in 
25 — between 12 and 24 months, in 32 — for over 
24 months. Four patients have been diagnosed in 
childhood due to interstitial lung disease.
Data obtained from anamnesis revealed the 
exposure to one or more allergens in 127 of HP 
patients (94%): poultry — in 40 patients, pigeons 
— in 29 patients, parrots — in 10 pts, microor-
ganisms present in hay and hay products — in 
51 patients, other exposures — in 28 cases. In 
18 subjects — the contact with allergens was not 
confirmed. Precipitins to birds’ proteins have 
been found in 68 patients, the precipitins to ther-
mophilic bacteria present in hay products — in 
26 patients. 
Chest CT results have been available in all 
of the patients. The features characteristic of HP 
have been reported in 117 subjects (87%). In the 
remaining ones — lung fibrosis without charac-
teristic pattern of HP has been described. 
BAL has been performed in 109 patients. 
Lymphocytosis exceeding 30% was found in 94 
out of 109 patients (86%). In 6 patients BAL lym-
phocyte count was between 20% and 30%, in the 
remaining 9 — it was lower than 20%. 
Transbronchial lung biopsy (TBLB) was 
performed in 37 patients, HP diagnosis has been 
confirmed — in 18 (49%). Surgical lung biopsy 
(SLB) was carried out in 40 subjects (in 5 — after 
negative result of transbronchial lung biopsy). 
The diagnosis of HP has been confirmed in 35 
cases (88%). 
Basing on the obtained data, the patients 
have been classified according to the categories 
described by Vasakova et al. [13]. In 73 patients 
(54%), the diagnosis of HP has been confident, 
in 21(16%) — probable, in 35(26%) — possible 
and in 6(4%) — unlikely. Among 21 patients with 
probable diagnosis of HP — the reason for such 
classification has been the lack of confirmation of 
exposure — in 12 patients, or lack of characteristic 
chest CT features of HP — in 9. Among the patients 
with possible diagnosis of HP, the lack of BAL 
was the reason for such classification in 22, and 
lymphocytosis lower than 30% — in 13 patients. 
Data concerning the results of lung biopsy 
in different diagnostic categories have been pre-
sented in Table 1. 
Lung biopsy has been performed in 41 out 
of 73 patients with confident diagnosis. All 19 
SLBs (100%) and 11 out of 24 TBLBs (46%) have 
been positive. Among 13 biopsies conducted in 
21 patients with probable diagnosis, 9 have been 
positive: 6 out of 7 SLBs (86%) and 3 out of 6 
TBLBs (50%). Among 17 biopsies performed in 
35 patients with possible diagnosis, 10 have been 
positive: 7 out of 10 SLBs (70%) and 3 out of 7 
TBLBs (43%). Among 4 surgical biopsies carried 
out in 6 patients with unlikely diagnosis, 3 have 
been positive (75%). 
Clinical diagnostic criteria of HP
1. Typical HRCT 
pattern of HP
2. Positive history 
of exposure
3. BAL — lympho-
cytosis
CONFIDENT HP
1. Typical HRCT 
pattern of HP
2. Negative history 
of exposure
3. BAL — lympho-
cytosis
PROBABLE HP
1. Typical HRCT 
pattern of HP or 
HRCT patterns of 
UIP, NSIP, CPFE, OP
2. Negative history 
of exposure
3. BAL — not 
performed or 
without 
lymphocytosis
1. HRCT pattern of 
UIP, NSIP, CPFE, 
OP
2. Positive history 
of exposure
3. BAL — lympho-
cytosis
PROBABLE HP
1. Typical HRCT 
pattern of HP
or HRCT pattern of 
UIP, NSIP, CPFE, 
OP
2. Positive history 
of exposure
3. BAL — not 
performed or 
without 
lymphocytosis
POSSIBLE HP UNLIKELY HP
Figure 4. Clinical	HP	probability	algorithm
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Table 1. Lung biopsy results, according to different diagnostic clinical categories in 77 hypersensitivity pneumonitis (HP) patients
Type of biopsy Clinical diagnostic category of HP
Confident 
no (%)
Probable
no (%)
Possible
no (%)
Unlikely
no (%)
Total
no (%)
TBLB	
Positive
Negative
Total
11	(46%)
13
24
3	(50%)
3
6
3	(43%)
4
7
0
0
0
17	(46%)
20
37
SLB	
Positive
Negative
Total
19	(100%)
	0
19
6	(86%)
1
7
7	(70%)
3
10
3	(75%)
1
4
35	(88%)
5
40
TBLB:	transbronchial	lung	biopsy;	SLB:	surgical	lung	biopsy
Overall, the confirmation of HP with lung 
biopsy results have been obtained in 9 out of 21 
probable cases of HP (43%), 10 out of 35 possi-
ble cases of HP (29%), and in 3 out of 6 unlikely 
cases (50%). 
Thus, in 95 out of 135 patients (70%) with 
HP recognised in the period of 2005–2015, the 
diagnosis could be confirmed according to re-
cently proposed diagnostic criteria: in 54% due 
to confident clinical diagnosis, in 16% with non-
confident diagnosis — after confirmation with 
lung biopsy. The reason for the lack of proof of 
HP in 30% of the subjects was as follows: negative 
SLB — in 4%, and contraindications to invasive 
diagnostic procedures — in 26%. 
Discussion
HP, recognised in our centre in 135 patients, 
fulfilled the current diagnostic criteria in 95 cases 
(70%), in 73 — due to confident clinical diagnosis, 
and in 22 with non-confident clinical diagnosis 
— due to positive result of lung biopsy. 
First step of HP recognition, the identification 
of causative antigen, has been shown in 94% of 
patients. These data indicate the high rate of anti-
gen confirmation in the presented material, other 
authors documented positive history of exposures 
in 70–89% of patients [12, 21]. Most frequent 
exposures in the present study concerned con-
tacts with dump hay or hay products, poultry and 
pigeons. In 6% of patients, the causative agent 
has not been identified. As the list of described 
allergens is enlarging, medical anamnesis has to 
be composed of many questions, to confirm the 
occupational, or environmental exposure [13]. 
Precipitins to birds’ antigens have been 
discovered in 68 patients (in 48 of them, the 
exposure to birds proteins have been confirmed). 
The presence of precipitins to birds’ antigens in 
the patients without confirmed exposure, but 
otherwise fulfilling the criteria of HP, may be of 
clinical value in HP diagnosing. 
The median time to diagnosis was 12 months, 
in 120 subjects (88%) it was longer than 6 mon-
ths. Thus, according to current classification, the 
majority of patients presented with chronic HP. 
Radiological pattern of HP, which is very cha-
racteristic in the acute phase of the illness, may be 
more difficult to recognise in the chronic phase, 
especially when the distribution of fibrotic areas 
mimic nonspecific interstitial pneumonia (NSIP) 
or usual interstitial pneumonia (UIP). Neverthe-
less, in our material, in 117 out of 135 patients 
(87%), features characteristic of HP have been 
present in chest CT. Most of the patients presented 
with mosaic lung attenuations and occasionally 
— with air trapping. Upper and middle parts of 
the lungs have been most extensively affected. 
The recent publication of Salisbury et al. [17] 
has indicated that predominance of mosaic at-
tenuation and air trapping over reticulation are 
most predictive of HP in chronic phase of disease. 
Comparing to other interstitial lung diseases, 
HP is presenting with highest number of lympho-
cytes in BAL. There is no consensus in the litera-
ture concerning the measures that would be use-
ful in HP diagnosing, the proposed cut-off values 
range from 20% to 50% [15, 22]. Higher cut-offs 
have to be probably used in case of differential 
diagnosis between HP and such interstitial lung 
diseases as: sarcoidosis, organising pneumonia or 
NSIP [8, 15]. In chronic phase of HP, lymphocyte 
counts may be lower, especially in smokers [8, 
12, 13, 23]. In our material, BAL lymphocytosis 
exceeding 30% was found in 94 out of 109 pa-
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tients (86%), despite the fact that the majority of 
them presented with chronic disease. On grounds 
of this finding, we suggest BAL performance in 
every patient with HP suspicion, even in those 
with fibrotic lung disease. It may be especially 
important in case of fibrotic HP mimicking UIP, 
as in UIP patients, the percentage of lymphocytes 
in BAL is usually below 20% [21]. 
Transbronchial lung biopsy has been dia-
gnostic of HP in 46% of patients. The percentage 
of positive TBLB results have been comparable 
in all diagnostic categories of HP, indicating that 
the results are mostly influenced by lower sen-
sitivity of this method comparing to SLB, and not 
by clinical HP probability. Surgical lung biopsy 
produced much higher diagnostic yield in our 
material, confirming the HP diagnosis in 88% of 
patients (in 100% of confident cases, but also in 
70–86% of the remaining categories). 
According to current recommendations, 
patients with confident clinical diagnosis of HP 
wouldn’t be referred to surgical lung biopsy. Ne-
vertheless, in our study group, the qualification 
for SLB has been performed between 2005 and 
2015, and many patients were referred to our 
Surgical Department from other centres. 
Despite lower sensitivity of TBLB compa-
ring to SLB, in our opinion, the patients with 
non-confident clinical diagnosis of HP should 
be first referred to TBLB, because it is less inva-
sive and combined with fewer complications 
[24]. In the period of 2005–2015, we had no 
experience with transbronchial cryobiopsy. The 
results obtained recently by other authors are 
encouraging [13, 15].
 On the basis of the obtained data, we conc-
lude that every effort should be made to enlarge 
the number of patients diagnosed as confident 
HP. Most important steps include the following: 
1. Identification of responsible antigen via de-
tailed anamnesis.
2. Clinical and radiological consulting in case of 
less typical radiological disease appearance.
3. Performing BAL (in search of increased lym-
phocytosis) in all suitable patients with HP 
suspicion. 
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